1. Home
  2. HLI vs TGTX Comparison

HLI vs TGTX Comparison

Compare HLI & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Houlihan Lokey Inc.

HLI

Houlihan Lokey Inc.

HOLD

Current Price

$131.20

Market Cap

9.7B

Sector

Finance

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$54.99

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HLI
TGTX
Founded
1972
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
8.5B
IPO Year
2015
2008

Fundamental Metrics

Financial Performance
Metric
HLI
TGTX
Price
$131.20
$54.99
Analyst Decision
Buy
Buy
Analyst Count
11
8
Target Price
★ $155.44
$69.71
AVG Volume (30 Days)
680.6K
★ 1.4M
Earning Date
10-28-2026
11-06-2026
Dividend Yield
★ 2.10%
N/A
EPS Growth
6.87
★ 1746.67
EPS
★ 1.15
0.17
Revenue
★ $2,617,516,000.00
$2,785,000.00
Revenue This Year
N/A
$55.81
Revenue Next Year
$18.82
$37.36
P/E Ratio
★ $115.93
$311.47
Revenue Growth
★ 9.55
N/A
52 Week Low
$112.83
$26.76
52 Week High
$204.18
$59.30

Technical Indicators

Market Signals
Indicator
HLI
TGTX
Relative Strength Index (RSI) 52.69 51.71
Support Level $121.89 $51.68
Resistance Level $133.34 $58.05
Average True Range (ATR) 4.00 2.17
MACD 0.60 -0.06
Stochastic Oscillator 72.46 64.75

Price Performance

Historical Comparison
HLI
TGTX

About HLI Houlihan Lokey Inc.

Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: